Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Diego Rolfo, Philip C. Mack, Giorgio V. Scagliotti et al. · Journal of Thoracic Oncology · 2018
Cited by 660 works. doi:10.1016/j.jtho.2018.05.030 Open-access PDF
Authors
- Christian Diego Rolfo
- Philip C. Mack
- Giorgio V. Scagliotti
- Fabrice Barlési
- Trever Grant Bivona
- Roy S. Herbst
- Tony S.K. Mok
- Nir Peled
- Robert Pirker
- Luis Estuardo Raez
- Martin Reck
- Jonathan Wesley Riess
- Lecia Van Dam Sequist
- Frances A. Shepherd
- Lynette Marie Sholl
- Daniel Shao-Weng Tan
- Heather A. Wakelee
- Ignacio Ivan Wistuba
- Murry W. Wynes
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Analyzing real-time PCR data by the comparative CT method
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
- Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- Circulating mutant DNA to assess tumor dynamics
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- Liquid Biopsies: Genotyping Circulating Tumor DNA